Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events such as heart attacks and strokes
This probably means you don’t need to worry about Lp(a) if ldl is already well controlled. Negative result for Novartis, that we all benefit from.
2 Likes
My very simplified understanding of Lpa is that it is mainly genetic and artificially lowering it doesn’t mean much, as it is only an indicator which foretells (somewhat) if people are in high risk category or not. In other words, if your LPa is optimal (naturally) you can do relatively better even if your LDL-c is somewhat high as opposed to someone whose LPa is naturally high but has same LDL-c as you.
And now we have a trial result that seems to confirm that.
1 Like
Let’s wait for the subgroup analysis and see if there’s any gold in there.
But I think this trial failure is completely normal. These patients were already on standard statin therapy, so it was always going to be hard to get further benefit. I suspect we might find some gold in the subgroup analyses stratified by baseline LP(a). There is currently no drug that specifically lowers LP(a), so I’m really looking forward to seeing this type of drug get approved. It would give biohackers who chase perfect numbers some more options.
1 Like
That’s a bit of relief for someone like me with high Lpa